A phase IV, open-label assessment of the treatment of actinic keratoses with diclofenac sodium 3% topical gel

被引：1
|
作者：
Rigel, DS
Swanson, N
Wolf, J
Smith, S
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 50卷 / 03期
关键词：
D O I：
10.1016/j.jaad.2003.10.421
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P479
引用
收藏
页码：P124 / P124
页数：1
相关论文
共 50 条
  • [31] A prospective double-arm, multicenter, open label phase IV evaluation of the use of diclofenac sodium 3% gel in the treatment of AK lesions post-cryosurgery
    Berlin, Joshua
    Rigel, Darrell
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB147 - AB147
  • [32] A novel topical agent in the treatment of seborrheic keratoses: An open-label pilot study with clinical and dermoscopic evaluation
    Lacarrubba, Francesco
    Nasca, Maria Rita
    Verz, Anna Elisa
    Pulvirenti, Nella
    Micali, Giuseppe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB19 - AB19
  • [33] Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial
    Kang, S
    Goldfarb, MT
    Weiss, JS
    Metz, RD
    Hamilton, TA
    Voorhees, JJ
    Griffiths, CEM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (01) : 83 - 90
  • [34] Photographic results of the use of diclofenac sodium 3% topical gel in the treatment of rosacea
    Bikowski, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB31 - AB31
  • [35] Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series
    Vlachou, C.
    Al Kanelleas
    Martin-Clavijo, A.
    Berth-Jones, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (11) : 1343 - 1345
  • [36] Topical 3% Diclofenac in 2.5% Hyaluronic Acid GelA Review of Its Use in Patients with Actinic Keratoses
    Blair Jarvis
    David P. Figgitt
    American Journal of Clinical Dermatology, 2003, 4 : 203 - 213
  • [37] Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group
    Pflugfelder, A.
    Welter, A. -K.
    Leiter, U.
    Weide, B.
    Held, L.
    Eigentler, T. K.
    Dirschka, T.
    Stockfleth, E.
    Nashan, D.
    Garbe, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (01) : 48 - 53
  • [38] Diclofenac systemic bioavailability of a topical 1% diclofenac+3% menthol combination gel vs. an oral diclofenac tablet in healthy volunteers: a randomized, open-label, crossover study
    Moreira, Sebastian A.
    Liu, D. Jeffery
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (04) : 368 - 372
  • [39] Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses
    Ulrich, Claas
    Johannsen, Antje
    Roewert-Huber, Joachim
    Ulrich, Martina
    Sterry, Wolfram
    Stockfleth, Eggert
    EUROPEAN JOURNAL OF DERMATOLOGY, 2010, 20 (04) : 482 - 488
  • [40] Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0•015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp
    Stockfleth, E.
    Harwood, C. A.
    Serra-Guillen, C.
    Larsson, T.
    Osterdal, M. L.
    Skov, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 433 - 442
12345